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REVIEW
IMMUNOACTIVATION AND IMMUNOPATHOGENY DURING ACTIVE VISCERAL LEISHMANIASIS
Hiro GOTO(1,2) & Maria das Graças PRIANTI(1)
SUMMARY
Visceral leishmaniasis is caused by protozoan parasites of the Leishmania donovani complex. During active disease in humans, high 
levels of IFN-g and TNF-a detected in blood serum, and high expression of IFN-g mRNA in samples of the lymphoid organs suggest 
that the immune system is highly activated. However, studies using peripheral blood mononuclear cells have found immunosuppression 
specific to Leishmania antigens; this poor immune response probably results from Leishmania antigen-engaged lymphocytes being 
trapped in the lymphoid organs. To allow the parasites to multiply, deactivating cytokines IL-10 and TGF-b may be acting on 
macrophages as well as anti-Leishmania antibodies that opsonize amastigotes and induce IL-10 production in macrophages. These high 
activation and deactivation processes are likely to occur mainly in the spleen and liver and can be confirmed through the examination 
of organ samples. However, an analysis of sequential data from studies of visceral leishmaniasis in hamsters suggests that factors 
outside of the immune system are responsible for the early inactivation of inducible nitric oxide synthase, which occurs before the 
expression of deactivating cytokines. In active visceral leishmaniasis, the immune system actively participates in non-lymphoid organ 
lesioning. While current views only consider immunocomplex deposition, macrophages, T cells, cytokines, and immunoglobulins by 
diverse mechanism also play important roles in the pathogenesis.
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 Visceral leishmaniasis is caused by protozoa of the genus 
Leishmania that are transmitted to mammalian hosts, including humans, 
by phlebotomine sandflies. The disease is present in 66 countries in 
tropical and subtropical regions, and 90% of cases occur in India, Sudan, 
Bangladesh, Nepal, and Brazil. It is estimated that there are 500,000 
new cases a year worldwide68, and 3,000 new cases occur each year in 
Brazil48. Until recently, the disease was thought to be caused by three 
species of the Leishmania donovani complex: Leishmania (Leishmania) 
donovani, L. (L.) infantum, and Leishmania (L.) chagasi (a species present 
in Brazil). There is now debate, however, over whether L. (L). infantum 
and Leishmania (L.) chagasi are the same44 or different60 species. In this 
review, the names of the three species will be used as in the original 
publications. Leishmania (Leishmania) donovani is present in East Africa, 
India, and parts of the Middle East, while L. (L.) infantum in Europe, 
North Africa, and South and Central America. Human infections can 
be asymptomatic or can manifest as oligosymptomatic and progressive 
diseases; progressive cases can involve hepatosplenomegaly, fever, 
pancytopenia, hypergammaglobulinemia, and serious weight loss4. 
During active visceral leishmaniasis, the parasite multiplies within the 
cells of the mononuclear phagocyte system in the spleen, liver, and bone 
marrow, and the disease is fatal if untreated. 
Studies in experimental models using Leishmania major in inbred 
mouse strains suggest that protection from the disease comes from the 
Th1-type immune response that is initiated when interleukin (IL)-12 
acts on antigen-presenting cells, triggering Th1 CD4+ T cells to produce 
interferon-gamma (IFN-g) and tumor necrosis factor alpha (TNF-a). 
Susceptibility to the disease is attributed to the Th2-type immune response 
and the production of IL-4 and IL-1356. This dichotomy is not as clear 
in models of visceral leishmaniasis in mice caused by Leishmania 
donovani. Studies have found differences between these models and 
those of cutaneous leishmaniasis. CD4+ and CD8+ T cells are important 
for resistance to visceral leishmaniasis, and they are involved in the 
production of IL-2, IFN-g, and IL-12. The latter acts independently 
of IFN-g and is linked to the production of transforming growth factor 
beta (TGF-b). Susceptibility involves IL-10 (but not IL-4) and B cells30.
Because the immune response is severely affected during active 
visceral leishmaniasis, few studies have examined immune protective 
mechanisms in humans. Although immune protective mechanisms play 
a crucial role in resistance, some studies suggest that the development 
of the disease among infected people depends on factors outside of the 
immune system18 that have not yet been defined. A small proportion of 
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infected individuals develop the active disease, which is accompanied by 
considerable disturbance in the immune response. This review discusses 
alterations in immune response during the active disease, as well as the 
participation of immune elements in the lesions of non-lymphoid organs.
IMMUNOACTIVATION IN LYMPHOID ORGANS
Current view on alterations of the immune response during active 
visceral leishmaniasis refers to immunosuppression mostly specific to 
Leishmania antigens; tests for delayed-type hypersensitivity to these 
antigens (the Leishmanin or Montenegro tests) have been negative, and 
there is no Leishmania antigen-induced proliferative response of the 
peripheral blood mononuclear cells (PBMC)13,33,34, 42. Some studies show 
that the lymphoproliferative response to mitogens is also affected14,29,34 but 
it is primarily the Leishmania antigen-driven response that is disturbed. 
In addition, IL-12 is absent in Leishmania antigen-induced cytokine 
production in PBMC culture supernatants28, and IL-2 and IFN-g are either 
absent or present in low levels12,15,28,39. These findings reinforce the view 
that it is mainly the Th1 response that is suppressed. 
This understanding of immunosuppression, however, does not reflect 
other alterations of immune response that occur during active disease. 
Although some studies evaluating cytokines in serum samples have either 
not detected or found low concentrations of IFN-g63,69,70, other studies 
have produced conflicting results. IFN-g was detected in 17 of 44 patients 
in Iran2 and in 13 of 15 patients in Brazil20; in addition, high levels have 
been confirmed in patients in Asia, Europe, Africa, and Brazil 9,15,31,32,50,52. 
These differing results are most likely not related to the selected patient 
groups or to the Leishmania species involved, but rather to the samples 
that were analyzed. Two studies, for example, examined IFN-g levels 
in both the supernatant of Leishmania antigen-induced PBMCs and the 
serum; low levels were found in the first sample, while high levels were 
found in the second sample9,15. TNF-a, another cytokine important for 
protection, was also found at elevated levels in the serum20,70. 
IFN-g in the serum most likely comes from the lymphoid organs 
where Leishmania proliferates. There is little data directly supporting 
this view, however, since it is difficult to obtain tissue samples from 
patients with the active disease. However, IFN-g mRNA expression 
is, as expected, present and high in bone marrow36, lymph node27, and 
spleen38,50 aspirates.
These data suggest that during active visceral leishmaniasis the 
immune system is not suppressed, but is highly activated. This activation 
is most likely induced by Leishmania antigens and may occur mainly 
in the organs where the parasites thrive (such as the spleen, liver, and 
bone marrow) where the cells engaged in Leishmania antigen-induced 
immune response are probably trapped. Therefore, PBMCs would consist 
of a non-Leishmania antigen-specific population, which would fail to 
proliferate or produce cytokines upon Leishmania antigen stimulation. 
It is also possible that the PBMCs are pre-activated and cannot be 
further stimulated; this is less likely, however, since a study in Ethiopia 
compared individuals with active disease, cured disease, subclinical 
manifestations, asymptomatic disease, and no disease and found that 
memory (CD45RO+CD27+) CD4+ cells and naïve (CD45RO-CD27+) 
CD8+ cells were at their lowest levels in patients with the active disease31. 
Furthermore, the same study found that phorphol miristate acetate- and 
ionomycin-induced CD4+ and CD8+ cell IFN-g production was at its 
lowest level in patients with the active disease31.
It is important to point out that the known polyclonal activation of 
B cells in visceral leishmaniasis25 is probably also a part of this general 
activation of the immune system.
We observed that even though the immune system is highly activated 
and the main leishmanicidal cytokines IFN-g and TNF-a are produced, 
the parasitic infection still progresses. This indicates the existence of 
deactivating mechanisms that probably act on macrophages and allow 
Leishmania to multiply. Studies of PBMCs have suggested a variety of 
general suppressive mechanisms, including soluble factors5, different 
cells10, and the interactions of cytokines3; these studies do not, however, 
explain the progressive proliferation of parasites within macrophages in 
lymphoid organs during active visceral leishmaniasis. 
The role of cytokine interaction in suppression has been extensively 
explored and may better explain the progressive infection. Because it 
plays an important role in susceptibility to Leishmania major-induced 
cutaneous leishmaniasis56, levels of IL-4 have been examined in cases 
of human visceral leishmaniasis. The level of IL-4 in serum varies, and 
IL-4 was detected in some patients20,50,63,69 but not in others2,15,52. IL-4 
mRNA expression was detected in bone marrow in approximately half 
of the cases38. IL-13, which is also related to susceptibility, was detected 
in serum in some studies2,50. 
Another cytokine, IL-10, has been identified in experimental 
studies of cutaneous leishmaniasis as an important cytokine not only 
for susceptibility, but also for the persistence of the parasite in lesions7. 
It has also been found to be important in susceptibility to visceral 
leishmaniasis30,49. It has been detected in different samples of human 
visceral leishmaniasis: as mRNA in bone marrow36, lymph node27, and 
spleen38 aspirates and at high levels in serum1,2,15,40,50,52,63,69; for further 
information see51. As mentioned earlier, the possible effect of IL-10 on 
the production of, or proliferation of IFN-g producing cells11,28 may not be 
important given the high activation of the immune response in lymphoid 
organs during active disease. Rather, the effect seen with IL-10 from 
patient plasma on macrophages that allowed better parasite growth50 
should be considered important to the development of the disease. 
Transforming Growth Factor-b (TGF-b) is also important in 
leishmaniasis. High levels of total TGF-b were detected in sera in one 
study9 and levels similar to those in control individuals were detected in 
another ; TGF-b was also found to be highly expressed in bone marrow26 
and spleen50 samples. Its macrophage deactivating effect was observed 
both in vitro and in vivo6 and was found to affect NO production41.
Most of the activation and deactivation of the immune response 
during active visceral leishmaniasis should take place in the spleen 
and the liver. However, while Leishmania multiplies in these lymphoid 
organs, little is known about cell and cytokine interactions in these organs 
in humans. It is important to understand these interactions in order to 
develop treatments and vaccines. 
In the only published study analyzing cell populations and cytokine 
expression in human spleens50, the spleen aspirate was composed of 
70% lymphocytes, 4% plasma cells, 7% monocytes/macrophages, and 
10% neutrophils, with frequent blasts. Gated lymphocyte subsets that 
GOTO, H. & PRIANTI, M.G. - Immunoactivation and immunopathogeny during active visceral leishmaniasis. Rev. Inst. Med. trop. S. Paulo, 51(5): 241-246, 2009.
243
also included some CD14+ monocytes were analyzed, and B (CD19+) 
cells were present in a slightly smaller proportion than T (CD3+) cells. 
Cytokine mRNA expression in these cells showed the presence of IL-10, 
IFN-g, IL-4, TNF-a, and TGF-b. With specific treatment, the relatively 
high expression of IL-10, IFN-g, and TGB-b decreased significantly. IL-
10 and IFN-g expression was mainly in CD3+ cells, and in the remained 
cell population after the depletion of CD3+, CD19, and CD25+ cells; 
IL-10 in particular was not significantly expressed in CD4+CD25+ 
(Foxp3) regulatory cells. These findings reinforce the view that most 
of the activation and deactivation of the immune response takes place 
in lymphoid organs and that IFN-g and TNF-a are activating cytokines, 
while IL-10 and TGF-b are deactivating cytokines.
However, in the previously mentioned study, red pulp was apparently 
underrepresented in the spleen aspirate samples since the macrophages 
were present in small proportion; hyperplasia and hypertrophy of 
macrophages in the red pulp where parasites proliferate are known to 
be the dominant features of active visceral leishmaniasis67. It is likely 
that in active disease the deactivation of macrophages would take 
place in this area, but this issue should be better analyzed. A study of 
visceral leishmaniasis in mice contributes to our understanding of these 
interactions46. During the infection’s progression, the number of T 
and dendritic cells increased in the periarteriolar lymphoid sheath and 
marginal zone; at the same time, parasite proliferation in macrophages 
was occurring elsewhere, in the red pulp. The prominent production of 
IL-10 in the marginal zone and TGF-b in the red pulp was observed. 
The cytokines in these locations may play a role in the progression of 
the infection. While the emphasis in the literature has been on IL-10, 
these experimental data indicate that TGF-b must be better understood. 
In another study of experimental visceral leishmaniasis, the effect of a 
high TNF-a disorganizing marginal zone of white pulp was also found 
to be important to the progression of the infection37. 
The only study of the liver of human visceral leishmaniasis 
patients was restricted to cases with a nodular pattern. This pattern of 
liver pathology is generally present in cases or disease phases where 
the host’s protective response is present. The study examined nine 
cases, and some elements were semi-quantified in tissues subjected to 
immunohistochemistry59. Within the nodules, Leishmania amastigotes 
were present, along with IFN-g and TNF-a and few IL-10 producing 
cells. In addition to T, B, and NK cells, high numbers of plasma cells 
were also present. A considerable amount of TGF-b was detected but 
not quantified. Although the study was restricted to cases with a nodular 
pattern, the data again show the simultaneous presence of macrophage 
activating and deactivating cytokines; the smaller presence of the latter 
may be due to the selection criteria of the cases.
While anti-Leishmania antibodies have no protective role in 
leishmaniasis, some data suggest that they favor parasite growth. 
Mutant mice that are lacking mature B cells, for example, have an 
increased resistance to Leishmania donovani61. Furthermore, cutaneous 
lesion-derived amastigotes were shown to be coated by IgG, and when 
phagocytized by macrophages, they induced IL-10 production in vitro 
and favored parasite growth35. Similarly, IgG-free axenic L. chagasi-
infected human monocytes do not produce IL-10, but high levels of IL-
10 are observed within cells when amastigotes incubated with visceral 
leishmaniasis sera were used47. The same researchers have examined 
individuals living in areas where visceral leishmaniasis is endemic. They 
have found a negative correlation between anti-Leishmania antibody 
levels and delayed-type hypersensitivity induration size, and have 
found a positive correlation between high antibody levels and active 
disease47. This antibody-dependent mechanism may operate in the red 
pulp of the spleen or in the inflammatory foci of the liver, where plasma 
cells are multiplying, producing antibodies, and contributing to parasite 
multiplication.
Although these fractional data from human samples allow us to infer 
some of the mechanisms at work in the progression of the infection, 
experimental models would supply more extensive information. Recent 
observations of hamsters, for example, have highlighted important 
information45. In visceral leishmaniasis in hamsters, where the disease 
manifests similarly to in humans, parasites continued to replicate in the 
spleen, liver, and bone marrow, and IL-2, IFN-g, and TNF/lymphotoxin 
were detected in these organs. However, inducible nitric oxide (NO) 
synthase mRNA or synthase activity was not detected in either the liver 
or spleen. No explanation for this finding was offered. There was no 
expression of IL-4 mRNA, and the expression of IL-10 mRNA occurred 
late in the disease’s progression, while the inactivation of NO synthase 
was present from the beginning. While TGF-b mRNA expression 
in the spleen was not very high, the active form of TGF-b increased 
but also occurred late in the disease’s progression. This discrepancy 
between TGF-b mRNA expression and active TGF-b may be due to the 
presence of cathepsin B in L. donovani and L. chagasi. These species 
have a cathepsin B-like gene that plays a role in the growth of parasites 
within macrophages, and the cathepsin B protein has the ability to 
directly activate TGF-b62. Another finding from this study, the decreased 
expression or inactivation of inducible NO synthase, may be caused by 
the arginase activation of Leishmania, which may lead to an alternative 
activation of the macrophages. We raise this hypothesis since we observed 
the activation of arginase of L. amazonensis and infected macrophages 
in the presence of insulin-like growth factor-I66, which is present in the 
various tissues.
In active visceral leishmaniasis, the immune system is highly 
activated and produces both the macrophage-activating cytokines 
IFN-g and TNF-a and the macrophage-deactivating cytokines IL-10 
and TGF-b. However, recent experimental data suggest that parasitic 
factors are also important. Cathepsin B, for example, directly activates 
TGF-b, and parasitic arginase is activated by a non-specific host factor 
(insulin-like growth factor-I), which activates the macrophages and 
inhibits inducible NO and NO production. Furthermore, these parasite-
dependent factors and non-specific host factors may play more of a role 
in the development of the active disease in areas where it is endemic. 
While the study of genetic susceptibility is currently focused on genes 
related to the immune system, it should be expanded to examine genes 
outside of the immune system. 
IMMUNOPATHOGENY IN NON-LYMPHOID ORGANS
During infection organs outside of the mononuclear phagocyte system 
are also affected23. In these other organs, mononuclear cell inflammatory 
infiltrate appears in the presence of few Leishmania antigens; this 
appearance suggests that immune mechanisms play a role in lesioning. 
Studies of lungs have observed multifocal interstitial pneumonitis, a 
process that is driven by Leishmania antigens21 and the participation of 
immune elements. Recently, the inflammatory process constituted by 
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mononuclear cells was characterized, and shown to be constituted by 
macrophages and CD8+ T cells. The expressions of IL-4 and TNF-a 
were high when compared to normal lungs64. In hamsters with visceral 
leishmaniasis, a transient IgG deposit was observed in the capillary 
walls of the lungs; it increased in intensity until day 30 of the infection 
and then declined. There were no significant C3b deposits at any time43, 
which suggests that a mechanism other than immune complex deposition 
was at work. The time course of various elements and their interactions 
must be better studied. 
The kidney is by far the best studied organ, and there have been 
several studies of renal alterations in human visceral leishmaniasis22,24. 
Dogs and hamsters with visceral leishmaniasis presenting lesions 
similar to those in humans are used as models to understand human 
pathology16,57. Until recently, studies of glomerular alterations in 
visceral leishmaniasis pathogenesis have only found immune complex 
deposition19,53,58. However, since other studies of glomerulonephritis 
pathogenesis of other etiologies have revealed the involvement of T 
cells65 and adhesion molecules8 we extended our study to evaluate the 
participation of other immune elements. We detected CD4+ T cells in 
the glomeruli of five dogs with naturally acquired visceral leishmaniasis 
from an area where the disease is endemic17. Furthermore, in a parallel 
study we identified glomerulonephritis in 55 dogs naturally infected 
with visceral leishmaniasis, characterized their glomerular alterations 
histopathologically, and classified them into six different patterns 
(proliferative patterns were most common)16. Both studies strongly 
suggested that the migration and proliferation of cells, including T 
cells, plays a role in the pathogenesis of glomerulonephritis in visceral 
leishmaniasis. Other immune elements were later analyzed (COSTA et 
al., submitted), and we observed the Leishmania antigen in glomeruli cells 
in 98% of animals; CD4+ T cells were observed in the glomeruli of most 
animals, CD8+ T cells were observed to a lesser extent, and no T cells 
were observed in non-infected controls. Deposits of immunoglobulin and 
C3b did not differ between infected animals and non-infected controls, 
which suggests that they play no significant role in these animals due 
to chronic evolution. Since a proliferative marker Ki-67 was not locally 
detected, CD4+ T cells may have migrated into the glomeruli, with 
contribution of adhesion molecules and the diminished apoptosis of cells 
maintaining the proliferative pattern of glomerulonephritis in visceral 
leishmaniasis. 
We are currently using experimental models of visceral leishmaniasis 
to examine the time course and interplay of various immune elements in 
the pathogenesis of glomerulonephritis. Models in mice do not reproduce 
the progressive visceral leishmaniasis of humans but in this species 
reagents for different markers are easily available. We recently described 
the mouse model in depth and showed that it is useful to the study of 
the pathogenesis of glomerulonephritis54. Initial studies in this model 
show the early proliferation of macrophage/phagocytes in glomeruli and 
the presence of mainly CD4+ T cells; these findings correspond to our 
observations of canine visceral leishmaniasis55.
All of the data from animal models and from the lungs and kidneys of 
visceral leishmaniasis patients show that immune elements play an active 
role in lesioning; these elements include immunoglobulins, macrophages, 
T cells, and certain cytokines. Immunocomplex deposits may occur in 
certain cases, but immunoglobulins appear to participate both transiently 
and through alternative mechanisms that are not yet clear. 
CONCLUDING REMARKS
While it is often assumed that immunosuppression occurs during active 
visceral leishmaniasis in humans, the immune system is in fact highly 
activated and produces macrophage-activating cytokines such as IFN-g 
and TNF-a as well as macrophage-deactivating cytokines such as IL-10 
and TGF-b. These high activation and deactivation processes are likely to 
occur mainly in the spleen and liver, and it is likely that peripheral blood 
mononuclear cells respond poorly to Leishmania antigens because antigen-
engaged lymphocytes are trapped in the lymphoid organs. To understand 
the process of infection and disease, it is important to analyze the lymphoid 
organs. Studies must examine the regions that involve amastigote-harboring 
macrophages and the localization of various immune elements.
Data from animal models of visceral leishmaniasis must be critically 
and carefully analyzed if they are to guide observations in humans. 
Since there are many unanswered questions about the factors that lead 
to disease development in infected people, the role of parasite-related 
and non-specific host factors must be taken seriously. 
In active visceral leishmaniasis, the immune system actively 
participates in non-lymphoid organ lesioning. Further studies are 
needed to identify the mechanisms through which macrophages, T cells, 
cytokines, and immunoglobulins participate in pathogenesis.
Studies of immune activating and deactivating processes as well as 
immunopathogenic mechanisms may contribute to the better management 
of the disease and to the development of treatment alternatives. 
RESUMO
Imunoativação e imunopatogenia durante  
leishmaniose visceral ativa
A leishmaniose visceral é causada por protozoários do gênero do 
complexo Leishmania donovani. Durante a doença ativa no homem são 
detectados altos níveis de IFN-g e de TNF-a no soro, e elevada expressão 
de mRNA de IFN-g em amostras de órgãos linfóides sugerindo um estado 
intensamente ativado do sistema imunológico. A visão atual, no entanto, 
refere-se à imunossupressão específica aos antígenos de Leishmania com 
base em estudos utilizando células mononucleares do sangue periférico; 
a explicação para sua resposta deficiente seria provavelmente porque os 
linfócitos compometidos com antígeno de Leishmania são sequestrados 
nos órgãos linfóides. Para permitir a proliferação do parasito, citocinas 
desativadoras IL-10 e TGF-b atuariam nos macrófagos, bem como os 
anticorpos anti-Leishmania opsonizando amastigotas e induzindo a 
produção IL-10 pelos macrófagos. Estes processos de intensa ativação e 
desativação provavelmente ocorreriam no baço e fígado, principalmente, 
e confirmados com amostras de órgãos. No entanto, analisando dados 
seqüenciais obtidos na leishmaniose visceral no hamster, sugere-
se provável presença de fatores fora do sistema imunológico como 
responsável pela inativação inicial de sintase induzível do óxido nítrico 
que ocorre antes da expressão de citocinas desativadoras. Na leishmaniose 
visceral ativa o sistema imunológico participa ativamente na lesão de 
órgãos não linfóides. Contrária à visão existente que considera somente 
mecanismos de deposição de imunocomplexos, observa-se na patogenia 
a participação de macrófagos, células T, citocinas e imunoglobulinas por 
mecanismo alternativo. 
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